Franco Aversa

58 O - Successful engraftment of t-cell-depleted HLA-incompatible transplants

Since March 1993, 48 patients (mean age 22 years, range 2–51) with high-risk or advanced stage leukemia (14 AML, 31 ALL, 3 CML) have been transplanted. 26 were in hematological remission (5 CR I, 20 CRxa0≥xa0II. 2nd CP of CML) and 22 (11 AML, 9 ALL. 2 BT) in chento-resistant relapse at the time of transplant. All donors were HLA-haploidentical “three loci” incompatible family members. The first 36 patients received a conditioning regimen that included single TBI (8xa0Gy), 25xa0mg/kg rabbit ATG. 10xa0mg/kg thiotepa and 100xa0mg/kg cyclophosphamide (Cy). In the last 12 Cy was replaced by fludarabine (40xa0mg/m2/day for 6 days) and thiotepa increased to 13xa0mg/kg. T-cell-depletion of the bone marrow and the PBPCs by the soybean agglutinin and E-rosetting technique was the sole prophylaxis for GvffD in the first 36 patients, while a CD34-selection of E-rosetted PBPCs bas been used for the last 12 cases. 46 patients engrafted. GvHD occurred in 6; 9 re1apsed. 18 survive. 16 event-free at a median follow. Up of 12 months (range 1–33) The details of the clinical data will be presented.